TrialPharmacoEconomics2021

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia.

Carla Mamolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.